 David Irwin
Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemoglobins | 10 | 2021 | 315 | 3.430 |
Why?
| | Anemia, Sickle Cell | 9 | 2023 | 215 | 3.380 |
Why?
| | Hypoxia | 10 | 2022 | 957 | 1.250 |
Why?
| | Altitude | 4 | 2022 | 432 | 1.230 |
Why?
| | Hypertension, Pulmonary | 7 | 2022 | 1728 | 1.110 |
Why?
| | Altitude Sickness | 3 | 2016 | 172 | 1.080 |
Why?
| | Hemopexin | 3 | 2021 | 13 | 0.970 |
Why?
| | Pulmonary Edema | 2 | 2019 | 115 | 0.950 |
Why?
| | beta-Thalassemia | 1 | 2023 | 23 | 0.870 |
Why?
| | Pulmonary Ventilation | 1 | 2022 | 72 | 0.800 |
Why?
| | Haptoglobins | 3 | 2018 | 47 | 0.760 |
Why?
| | Vascular Remodeling | 3 | 2022 | 153 | 0.740 |
Why?
| | Rats | 15 | 2022 | 4958 | 0.730 |
Why?
| | Capillary Permeability | 4 | 2016 | 139 | 0.720 |
Why?
| | Beta vulgaris | 1 | 2020 | 4 | 0.720 |
Why?
| | Pulmonary Artery | 6 | 2022 | 1015 | 0.710 |
Why?
| | Endothelium, Vascular | 3 | 2018 | 847 | 0.680 |
Why?
| | Oxygen | 4 | 2022 | 854 | 0.670 |
Why?
| | Emulsions | 1 | 2019 | 42 | 0.670 |
Why?
| | Vasodilator Agents | 2 | 2013 | 302 | 0.660 |
Why?
| | Rats, Sprague-Dawley | 10 | 2019 | 2218 | 0.640 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 531 | 0.630 |
Why?
| | Blood Substitutes | 2 | 2009 | 27 | 0.630 |
Why?
| | Animals | 30 | 2023 | 31699 | 0.610 |
Why?
| | Lung | 4 | 2018 | 3559 | 0.610 |
Why?
| | Fluorocarbons | 1 | 2019 | 94 | 0.600 |
Why?
| | Microvessels | 1 | 2018 | 68 | 0.570 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.560 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2016 | 17 | 0.560 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 30 | 0.560 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 296 | 0.550 |
Why?
| | Cerebral Veins | 1 | 2016 | 15 | 0.550 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2016 | 22 | 0.550 |
Why?
| | Macrophages | 2 | 2023 | 1261 | 0.540 |
Why?
| | Water | 1 | 2019 | 396 | 0.540 |
Why?
| | Brain Edema | 1 | 2016 | 60 | 0.540 |
Why?
| | Cerebral Arteries | 1 | 2016 | 55 | 0.530 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2013 | 71 | 0.510 |
Why?
| | Muscle Contraction | 1 | 2018 | 389 | 0.490 |
Why?
| | Hemolysis | 4 | 2021 | 146 | 0.490 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 214 | 0.480 |
Why?
| | Atrial Natriuretic Factor | 2 | 2005 | 55 | 0.480 |
Why?
| | Endothelial Cells | 2 | 2013 | 685 | 0.470 |
Why?
| | Transcriptional Activation | 2 | 2013 | 337 | 0.450 |
Why?
| | Vascular Diseases | 2 | 2015 | 230 | 0.430 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 90 | 0.420 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 249 | 0.410 |
Why?
| | Oxygen Consumption | 2 | 2020 | 588 | 0.400 |
Why?
| | Mice | 13 | 2023 | 14863 | 0.360 |
Why?
| | Lung Diseases | 2 | 2015 | 701 | 0.330 |
Why?
| | Glutaral | 1 | 2009 | 14 | 0.330 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2009 | 36 | 0.320 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2009 | 82 | 0.320 |
Why?
| | Phenylpropionates | 2 | 2019 | 16 | 0.320 |
Why?
| | Muscle, Skeletal | 1 | 2018 | 1472 | 0.310 |
Why?
| | Disease Progression | 3 | 2023 | 2380 | 0.310 |
Why?
| | Sulfones | 1 | 2009 | 97 | 0.310 |
Why?
| | Pyridazines | 2 | 2019 | 46 | 0.310 |
Why?
| | Inflammation | 3 | 2023 | 2478 | 0.310 |
Why?
| | Vascular Resistance | 3 | 2016 | 337 | 0.300 |
Why?
| | Endothelins | 2 | 2018 | 61 | 0.300 |
Why?
| | Polymers | 2 | 2009 | 448 | 0.290 |
Why?
| | Piperazines | 1 | 2009 | 309 | 0.280 |
Why?
| | Lipid Peroxidation | 3 | 2018 | 139 | 0.270 |
Why?
| | Nitric Oxide | 3 | 2018 | 823 | 0.270 |
Why?
| | Disease Models, Animal | 7 | 2022 | 3532 | 0.270 |
Why?
| | Respiration | 2 | 2022 | 180 | 0.270 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 498 | 0.270 |
Why?
| | Male | 16 | 2021 | 55583 | 0.260 |
Why?
| | Cell Nucleus | 1 | 2009 | 554 | 0.260 |
Why?
| | Cardiac Output | 3 | 2012 | 143 | 0.250 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2017 | 411 | 0.250 |
Why?
| | Capillary Leak Syndrome | 1 | 2005 | 13 | 0.240 |
Why?
| | Neprilysin | 1 | 2005 | 47 | 0.230 |
Why?
| | Heme | 2 | 2021 | 52 | 0.230 |
Why?
| | Blood Pressure | 4 | 2018 | 1538 | 0.230 |
Why?
| | Mice, Inbred C57BL | 4 | 2018 | 4692 | 0.220 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 923 | 0.210 |
Why?
| | Endothelin-1 | 1 | 2005 | 167 | 0.210 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2015 | 154 | 0.210 |
Why?
| | Pulmonary Circulation | 2 | 2019 | 407 | 0.210 |
Why?
| | Humans | 20 | 2023 | 114662 | 0.200 |
Why?
| | Oxyhemoglobins | 1 | 2021 | 20 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 83 | 0.190 |
Why?
| | Magnetics | 1 | 2021 | 39 | 0.190 |
Why?
| | Scleroderma, Systemic | 1 | 2022 | 96 | 0.190 |
Why?
| | Alternative Splicing | 1 | 2022 | 187 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 493 | 0.180 |
Why?
| | Muscle Proteins | 1 | 2022 | 210 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2021 | 98 | 0.180 |
Why?
| | Monocytes | 1 | 2023 | 502 | 0.180 |
Why?
| | CD40 Antigens | 1 | 2021 | 82 | 0.180 |
Why?
| | Nitrates | 1 | 2020 | 72 | 0.170 |
Why?
| | RNA, Long Noncoding | 1 | 2022 | 154 | 0.170 |
Why?
| | Up-Regulation | 2 | 2013 | 807 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 194 | 0.170 |
Why?
| | Histone Deacetylases | 2 | 2012 | 195 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 161 | 0.160 |
Why?
| | Gadolinium | 1 | 2019 | 73 | 0.160 |
Why?
| | Enoyl-CoA Hydratase | 1 | 2018 | 9 | 0.160 |
Why?
| | Exercise Tolerance | 1 | 2020 | 213 | 0.160 |
Why?
| | Lipids | 2 | 2023 | 580 | 0.160 |
Why?
| | Antibodies | 1 | 2021 | 371 | 0.160 |
Why?
| | Double-Blind Method | 2 | 2020 | 1660 | 0.160 |
Why?
| | Metabolome | 1 | 2021 | 282 | 0.160 |
Why?
| | Cell Line | 2 | 2015 | 2636 | 0.160 |
Why?
| | Carrier Proteins | 1 | 2022 | 695 | 0.150 |
Why?
| | Liver Diseases | 1 | 2021 | 255 | 0.150 |
Why?
| | Blood Gas Analysis | 2 | 2008 | 72 | 0.150 |
Why?
| | Aminophylline | 1 | 2017 | 5 | 0.150 |
Why?
| | Proteomics | 1 | 2023 | 836 | 0.150 |
Why?
| | Antioxidants | 2 | 2013 | 530 | 0.140 |
Why?
| | Cell Proliferation | 2 | 2017 | 2186 | 0.140 |
Why?
| | Lipoproteins | 1 | 2018 | 159 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2014 | 3885 | 0.140 |
Why?
| | Mice, Knockout | 3 | 2022 | 2568 | 0.140 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 18 | 0.140 |
Why?
| | Acclimatization | 1 | 2018 | 149 | 0.140 |
Why?
| | Deferoxamine | 1 | 2016 | 18 | 0.140 |
Why?
| | Acetazolamide | 1 | 2016 | 30 | 0.140 |
Why?
| | Dietary Supplements | 1 | 2020 | 460 | 0.140 |
Why?
| | Niacinamide | 1 | 2016 | 63 | 0.130 |
Why?
| | Myocytes, Cardiac | 3 | 2022 | 449 | 0.130 |
Why?
| | Oxidative Stress | 2 | 2012 | 1076 | 0.130 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 429 | 0.130 |
Why?
| | NF-kappa B | 2 | 2013 | 641 | 0.130 |
Why?
| | Oligonucleotides | 1 | 2016 | 137 | 0.130 |
Why?
| | Signal Transduction | 5 | 2017 | 4512 | 0.130 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2018 | 348 | 0.130 |
Why?
| | Methemoglobin | 2 | 2021 | 19 | 0.130 |
Why?
| | Vasoconstriction | 1 | 2016 | 177 | 0.120 |
Why?
| | Indoles | 1 | 2016 | 304 | 0.120 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 141 | 0.110 |
Why?
| | Genomics | 1 | 2018 | 635 | 0.110 |
Why?
| | Chloride Channels | 1 | 2014 | 35 | 0.110 |
Why?
| | Cattle | 2 | 2008 | 921 | 0.110 |
Why?
| | RNA, Small Interfering | 3 | 2012 | 535 | 0.110 |
Why?
| | Catalase | 1 | 2013 | 118 | 0.110 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 83 | 0.110 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2012 | 198 | 0.110 |
Why?
| | Iron | 1 | 2015 | 233 | 0.110 |
Why?
| | Permeability | 1 | 2013 | 149 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2017 | 676 | 0.110 |
Why?
| | Ventricular Remodeling | 2 | 2012 | 226 | 0.110 |
Why?
| | Heart Failure | 2 | 2022 | 1945 | 0.100 |
Why?
| | Cyclic N-Oxides | 1 | 2012 | 30 | 0.100 |
Why?
| | Infusion Pumps | 1 | 2012 | 31 | 0.100 |
Why?
| | Spin Labels | 1 | 2012 | 44 | 0.100 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 1727 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 219 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 347 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 305 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 270 | 0.090 |
Why?
| | Cerebellum | 1 | 2013 | 200 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 287 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 2012 | 288 | 0.090 |
Why?
| | Microcirculation | 2 | 2014 | 135 | 0.090 |
Why?
| | Blotting, Western | 1 | 2012 | 1147 | 0.080 |
Why?
| | Pneumonia | 1 | 2015 | 567 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2009 | 57 | 0.080 |
Why?
| | Female | 7 | 2022 | 59493 | 0.080 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2009 | 110 | 0.080 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 38 | 0.080 |
Why?
| | Hypoxia, Brain | 1 | 2008 | 10 | 0.080 |
Why?
| | Purines | 1 | 2009 | 159 | 0.080 |
Why?
| | Hemodynamics | 1 | 2012 | 1012 | 0.070 |
Why?
| | Nitric Oxide Synthase | 1 | 2008 | 209 | 0.070 |
Why?
| | Exercise | 1 | 2017 | 1644 | 0.070 |
Why?
| | Norepinephrine | 1 | 2008 | 201 | 0.070 |
Why?
| | Dogs | 1 | 2008 | 334 | 0.070 |
Why?
| | Epinephrine | 1 | 2008 | 163 | 0.070 |
Why?
| | Protein Isoforms | 2 | 2022 | 338 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2013 | 2552 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2019 | 9088 | 0.070 |
Why?
| | Myocardium | 1 | 2011 | 913 | 0.060 |
Why?
| | Stroke Volume | 1 | 2008 | 504 | 0.060 |
Why?
| | Kidney | 1 | 2012 | 1188 | 0.060 |
Why?
| | Stress Fibers | 1 | 2004 | 16 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 750 | 0.060 |
Why?
| | Heart Rate | 1 | 2008 | 709 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 260 | 0.060 |
Why?
| | Hypertension | 1 | 2011 | 1056 | 0.050 |
Why?
| | Actins | 1 | 2004 | 381 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2177 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 94 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 49 | 0.050 |
Why?
| | Thrombin | 1 | 2023 | 139 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2018 | 3003 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2004 | 821 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 309 | 0.050 |
Why?
| | Etanercept | 1 | 2021 | 51 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2022 | 279 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 561 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 386 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1139 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 381 | 0.040 |
Why?
| | Tissue Donors | 1 | 2021 | 316 | 0.040 |
Why?
| | Heart | 1 | 2022 | 612 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 108 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 136 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 217 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2018 | 245 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2021 | 477 | 0.040 |
Why?
| | Cytoskeleton | 1 | 2018 | 176 | 0.040 |
Why?
| | Genetics, Population | 1 | 2018 | 188 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 228 | 0.040 |
Why?
| | Proteins | 1 | 2023 | 908 | 0.030 |
Why?
| | Heart Ventricles | 2 | 2012 | 712 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 385 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2014 | 396 | 0.030 |
Why?
| | Adenosine | 1 | 2017 | 203 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 1947 | 0.030 |
Why?
| | Sarcoma, Experimental | 1 | 2014 | 5 | 0.030 |
Why?
| | Rats, Nude | 1 | 2014 | 26 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 951 | 0.030 |
Why?
| | Intravital Microscopy | 1 | 2014 | 23 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1620 | 0.030 |
Why?
| | Adult | 3 | 2023 | 30544 | 0.030 |
Why?
| | Heterografts | 1 | 2014 | 117 | 0.030 |
Why?
| | Coronary Vessels | 1 | 2016 | 227 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1760 | 0.030 |
Why?
| | Swine | 1 | 2016 | 700 | 0.030 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 82 | 0.030 |
Why?
| | Mitochondria | 1 | 2018 | 747 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 1840 | 0.030 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2014 | 190 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 387 | 0.030 |
Why?
| | Chemistry, Physical | 1 | 2012 | 37 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 281 | 0.030 |
Why?
| | Young Adult | 2 | 2018 | 10466 | 0.030 |
Why?
| | Fructans | 1 | 1992 | 1 | 0.030 |
Why?
| | MicroRNAs | 1 | 2018 | 600 | 0.030 |
Why?
| | Genes, Immunoglobulin | 1 | 1992 | 26 | 0.030 |
Why?
| | Immunoglobulin Light Chains | 1 | 1992 | 35 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1518 | 0.030 |
Why?
| | Immunoglobulin Variable Region | 1 | 1992 | 72 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1992 | 72 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 1879 | 0.020 |
Why?
| | Histone Deacetylase 6 | 1 | 2011 | 19 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 169 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 2796 | 0.020 |
Why?
| | Adenoviridae | 1 | 2011 | 184 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 424 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 433 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 376 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4895 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 425 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 993 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 26733 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 2710 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1262 | 0.020 |
Why?
| | Child | 1 | 2023 | 18412 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2014 | 1862 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 17841 | 0.010 |
Why?
| | Antibody Diversity | 1 | 1992 | 16 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 1992 | 32 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1992 | 176 | 0.010 |
Why?
|
|
Irwin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|